The definitive guide to the science of psychedelics—"the perfect intro for anyone curious about psychedelics and MDMA” (Ethan Nadelmann, founder and former executive director, Drug Policy Alliance)--and how they can impact our health by world-renowned, leading authority Professor David Nutt.
We are on the cusp of a major revolution in psychiatric medicine and neuroscience. After fifty years of prohibition, criminalization and fear, science is finally showing us that psychedelics are not dangerous or harmful. Instead, when used according to tested, safe and ethical guidelines, they are our most powerful newest treatment of mental health conditions, from depression, PTSD, and OCD to disordered eating and even addiction and chronic pain.
Professor David Nutt, one of the world's leading Neuropsychopharmacologists, has spent 15 years researching this field and it is his most significant body of work to date. In 2018, he co-founded the first academic psychedelic research center - underpinned by his mission to provide evidence-based information for people everywhere. It revived interest in the understanding and use of this drug in its many forms, including MDMA, ayahuasca, magic mushrooms, LSD and ketamine. The results of this have been nothing short of ground-breaking for the future categorization of drugs, but also for what we now know about brain mechanisms and our consciousness.
At a time where there is an enormous amount of noise around the benefits of psychedelics, this book contains the knowledge you need to know about a drug that is about to go mainstream, free from the hot air, direct from the expert.
Are you ready to change your mind?
About the Author
David Nutt is Professor of Neuropsychopharmacology and director of the Neuropsychopharmacology Unit in the Division of Brain Sciences at Imperial College, London.
After completing his medical training at Guy's Hospital London, continuing in neurology to MRCP, he went on to his psychiatric training in Oxford, he continued there as a lecturer and then later as a Wellcome Senior Fellow in psychiatry. He then spent two years as Chief of the Section of Clinical Science in the National Institute of Alcohol Abuse and Alcoholism in NIH, Bethesda, USA. On returning to England in 1988 he set up the Psychopharmacology Unit in Bristol University, an interdisciplinary research grouping spanning the departments of Psychiatry and Pharmacology before moving to Imperial College London in December 2008 where he leads a similar group with a particular focus on brain imaging especially PET.
David is currently Chair of DrugScience (formally the Independent Scientific Committee on Drugs (ISCD) and President of the European Brain Council. previously he has been President of the European College of Neuropsychopharmacology (ECNP), the British Neuroscience Association (BNA) and the British Association of Psychopharmacology (BAP). In addition, he is a Fellow of the Royal Colleges of Physicians and of Psychiatrists and a Fellow of the Academy of Medical Sciences. He is also the UK Director of the European Certificate and Masters in Affective Disorders Courses and a member of the International Centre for Science in Drug Policy. He has edited the Journal of Psychopharmacology for over two decades and acts as the psychiatry drugs advisor to the British National Formulary.
Previously he has been a member and then Chair of the Advisory Committee on the Misuse of Drugs (ACMD - 1998-2009), a member of the HEFCE/NHS Senior Lecturer Selection Panel and of the MRC Neuroscience Board. Other previous national contributions include serving as the medical expert on the Independent Inquiry into the Misuse of Drugs Act (2000 Runciman report), and membership of the Committee on Safety of Medicines, the Committee on NHS drugs and the Ministry of Defence Science Advisory Board. He was the clinical scientific lead on the 2004/5 UK Government Foresight initiative "Brain science, addiction and drugs" that provided a 25-year vision for this area of science and public policy.
David broadcasts widely to the general public both on radio and television including BBC science and public affairs programmes on therapeutic as well as illicit drugs, their harms and their classification. He also lecturers widely to the public as well as to the scientific and medical communities; he has presented three time at the Cheltenham Science Festival and several times for Café Scientifiques.
When it comes to psychoactive drugs -- not one but all of them -- you don’t get much smarter than David Nutt. This book is Psychedelics 101 – the perfect intro for anyone curious about psychedelics and MDMA—Ethan Nadelmann, founder and former executive director, Drug Policy Alliance
“Finally! A balanced, accurate, sensible and readable book about psychedelics, ideal for anyone curious about the effects and equally so for people already involved in using and or researching psychedelics."—James Fadiman, PhD,, microdose researcher, author of The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys
“Psychedelics covers everything from definitions (including LSD, magic mushrooms, and ayahuasca), to discussions of what psychedelics do in the brain and how they may be useful for things like depression, drug dependence, trauma, anxiety, pain, and others. I heartily recommend this book to anyone who has been hearing about the development of psychedelics as medicines and wants to know more.”—David Nichols, PhD, Distinguished Professor Emeritus, Purdue University
“Psychedelics is a rare and exceptionally valuable book that provides a scientifically rigorous, historically insightful, and compassionate window into all the hope and hype in the psychedelic renaissance. Professor David Nutt’s lifetime of experience and knowledge has enabled him to create the ideal guide for everyone from novice to expert.” —Rick Doblin, Ph.D., President, MAPS
“When it comes to psychoactive drugs—not one but all of them—you don’t get much smarter than David Nutt. This book is Psychedelics 101—the perfect intro for anyone curious about psychedelics and MDMA.” —Ethan Nadelmann, founder and former executive director, Drug Policy Alliance